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Halmstad, Sweden; 2Copenhagen, Copenhagen University, Dept of Drug Design
and Pharmacology, Copenhagen, Denmark; 3Copenhagen, Nordic Bioscience,
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Background: Susceptibility to Rheumatoid Arthritis (RA) is dependent on
complex interactions among genetic and environmental factors. Protein
candidates and their role in pathways leading to chronic inflammation of
the joints, in addition to their potential as drug targets, can be revealed
with the help of experimental models for disease (1). From the results of
functional genetic studies, we have recently shown that the T-box gene,
TBX3, is a candidate gene in Collagen Induced Arthritis (CIA), an experi-
mental model for RA (2). TBX3 encodes a transcriptional regulator
involved in differentiation of several organs, including bone, during embry-
onic development. It has, in addition, been demonstrated important in
oncogenesis (3). Our studies suggest that TBX3 has a role in B-cell acti-
vation and is important for the severity of disease in the CIA model (2).
Objectives: The objective of this project is to understand the role for the
transcriptional regulator TBX3 in development of RA.
Methods: Bioinformatics based comparative studies of mouse and human
alleles in the regulatory region of TBX3. CRISPR/Cas9-introduced dele-
tions and base modifications in human B-cell lines. Activation of geneti-
cally modified B-cells in vitro, followed by analyses of proliferative
response and antibody production.
Results: Studies of CIA development in mice with single nucleotide poly-
morphisms (SNPs) in the regulatory region of Tbx3 revealed a significant
difference in severity of arthritis. In line with this, the anti-collagen type II
antibody titers were shown substantially higher in mice with more severe
arthritis, even before onset of disease. In addition, preliminary data shows
that the proliferative response to Type II collagen upon re-challenge of
lymph node cells in vitro is higher in these mice, suggesting a more
active response to the disease-inducing antigen. Because the TBX3 gene
is conserved between mouse and human, we are investigating whether
similar genetic variations are found in the regulatory region of the human
TBX3 gene and whether the putative genetic variation would lead to a
distinct B-cell phenotype upon activation in vitro.
Conclusion: We suggest that the oncoprotein TBX3 is a novel candidate
contributing to disease severity in experimental arthritis. Investigations of
genetic variation in the TBX3 gene and its role in the activation of
human B-cells will reveal whether this protein is a candidate for influenc-
ing also development of RA.
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Background: Tumor necrosis factor receptor-associated periodic syndrome
(TRAPS) stems from autosomal dominantly inherited mutations in the
TNFRSF1A (accession number: NM_001065) gene, encoding for the
receptor of tumor necrosis factor a (TNFR1).
Objectives: The aim of the study was to report a novel TNFRSF1A
mutation and to describe the clinical phenotypes in families carrying dif-
ferent TNFRSF1A mutations.
Methods: Four Greek patients with TRAPS-like clinical features were evaluated
for TNFRSF1A gene mutations. Direct sequencing of exons 2, 3 and 4 of the gene
was performed. Following positive testing of the index cases, samples from other
family members were collected and screened.
Results: A total of eighteen members deriving from four unrelated Greek
families were investigated. In the first family, a novel (heterozygous)
mutation in cysteine residue in exon 3 of the TNFRSF1A gene C73Y
(c.305G>A) was identified in three members. Interestingly, in the same
family a patient carrying the low penetrance TNFRSF1A R92Q mutation,
as well as a patient with concomitant R92Q and C73Y mutations were
identified. In the second family, the TNFRSF1A C73W (c.306C>G) hetero-
zygous mutation was identified in seven members. In the third family, the
TNFRSF1A T50M mutation was detected in two members while in the
fourth family six members carried the TNFRSF1A R92Q mutation in het-
erozygous state.
Clinical manifestations amongst members of the affected families were
diverse with the most serious being present in patients carrying the
TNFRSF1A C73Y, C73W and T50M mutations. Cardinal features included
disease onset in childhood (66.7% for C73Y, 85.7% for C73W and 100%
for T50M), arthritis (67% for C73Y, 100% for C73W and 100% for
T50M), persistent pyrexia (67% for C73Y, 100% for C73W and 100% for
T50M), abdominal pain (66.7% for C73Y, 100% for C73W and 100% for
T50M), recurrent adhesive ileus (33.3% for C73Y, 14.3% for C73W and
100% for T50M) anterior uveitis (33.3% for C73Y), and diffuse maculo-
papular rash (14.3% for C73W and 50% for T50M). The clinical presenta-
tion was more severe in the patient with concomitant R92Q and C73Y,
suggesting an additive effect. On the contrary, (as expected) the disease
spectrum associated with R92Q mutation found in six members encom-
passed a mild phenotype, extending from asymptomatic state (four mem-
bers) to adult-onset disease associated with intermittent low-grade fever,
arthritis and elevated inflammation markers (two members).
Conclusion: This was the first pedigree analysis of TRAPS in Greece,
depicting four families with unique mutations, along with analysis of the
clinical manifestation. The site of mutation might explain the diversity of
clinical phenotypes in TRAPS patients that extends from mild to severe
disease. In our patients, it appeared that mutations in the cysteine resi-
dues as well as in T50M were associated with more severe clinical man-
ifestations. Among these was a novel mutation described for the first
time in the literature.
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Background: In the last few years, an association has been described
between lower bone mass at the onset of disease and higher severity of
rheumatoid arthritis (RA).
Objectives: To identify single nucleotide polymorphisms (SNPs) in genes
related to bone remodeling associated with severity of disease and bone
mineral density (BMD) in patients with early-onset arthritis.
Methods: We included 268 PEARL (Princess Early Arthritis Register Lon-
gitudinal) patients genotyped with Ilumina Inc. Immunochip. This array
includes 556 SNPs with different density levels in semaphorins 4b, 4d
and 4f, DKK1, 2 and 3, sclerostin, osteoprotegerin (OPG), RANK and
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